NanoMedex Pharmaceuticals, Inc.

Company Profile

Industry Sector: Pharmaceuticals

Company Overview: NanoMedex Pharmaceuticals, Inc. has developed a formulation strategy to allow drugs that are only soluble in oil to be soluble in water.

Target Market(s): Anesthetics, Chemotherapeutics, Anti-inflammatory, Anti-arrhythmics, Immunosuppressants, Anti-infectives, Vitamins

Key Value Drivers

Technology: Microemulsion manufacturing for water insoluble pharmaceuticals.

Competitive Advantage: Less expensive to manufacture. Improved safety.

Plan & Strategy: Manufacture and market propofol as proof of principle product and expand into other products directly or through licensing.

Management

Leadership: David L. Cooper, MD, PhD, President and CEO
Kenneth U. Johnson, Director, Kegonsa Capital Partners
Jeffery C. Girard, Director, Shopko Stores
Nikolaus Gravenstein, MD, Director, University of Florida
Timothy E. Morey, MD, Director, University of Florida

Scientific Advisory Board: Dinesh Shah, PhD

Product Pipeline

- Anesthetics
  - Propofol

- Chemotherapeutics
  - Paclitaxel
  - Doxorubicin
  - Imotecan* (orphan)

- Anti-inflammatory
  - Ibuprofen

- Anti-arrhythmics
  - Amiodarone

- Immunosuppressants
  - Cyclosporine

- Anti-infectives

- Vitamins